Quarterlies round-up: AngioDynamics ends year on sales and earnings high
This article was originally published in Clinica
Executive Summary
A strong 56% increase in domestic sales, partially offset by a weak international performance, led to an overall 47% increase in product revenues for Abiomed's first quarter of fiscal 2005. A rise in sales of its new AB5000 ventricles, AB5000 consoles and BVS blood pump accounted for the largest share of revenue growth. The Danvers, Massachusetts company also saw a 25% reduction in quarterly net loss compared with the same period last year.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.